Prudential Financial Inc. cut its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 10.3% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 556,548 shares of the specialty pharmaceutical company’s stock after selling 63,849 shares during the period. Prudential Financial Inc. owned 0.92% of Jazz Pharmaceuticals PLC worth $67,610,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its stake in Jazz Pharmaceuticals PLC by 4.2% in the second quarter. Bank of New York Mellon Corp now owns 1,233,053 shares of the specialty pharmaceutical company’s stock valued at $174,242,000 after buying an additional 49,967 shares in the last quarter. Wells Fargo & Company MN raised its stake in Jazz Pharmaceuticals PLC by 17.2% in the third quarter. Wells Fargo & Company MN now owns 506,079 shares of the specialty pharmaceutical company’s stock valued at $61,478,000 after buying an additional 74,342 shares in the last quarter. Fiera Capital Corp acquired a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at approximately $46,955,000. BlackRock Advisors LLC raised its stake in Jazz Pharmaceuticals PLC by 1.9% in the second quarter. BlackRock Advisors LLC now owns 326,200 shares of the specialty pharmaceutical company’s stock valued at $46,095,000 after buying an additional 6,012 shares in the last quarter. Finally, Victory Capital Management Inc. raised its stake in Jazz Pharmaceuticals PLC by 35,390.5% in the third quarter. Victory Capital Management Inc. now owns 303,444 shares of the specialty pharmaceutical company’s stock valued at $36,863,000 after buying an additional 302,589 shares in the last quarter. Institutional investors and hedge funds own 89.70% of the company’s stock.

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 105.84 on Wednesday. The firm has a market cap of $6.34 billion, a price-to-earnings ratio of 18.51 and a beta of 1.35. Jazz Pharmaceuticals PLC has a 52 week low of $95.80 and a 52 week high of $160.00. The stock’s 50 day moving average is $113.78 and its 200 day moving average is $132.31.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, November 8th. The specialty pharmaceutical company reported $2.57 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.61 by $0.04. The firm had revenue of $374 million for the quarter, compared to analyst estimates of $389.34 million. Jazz Pharmaceuticals PLC had a net margin of 24.81% and a return on equity of 30.50%. The firm’s revenue for the quarter was up 9.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.52 EPS. Equities research analysts expect that Jazz Pharmaceuticals PLC will post $9.96 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Stake Cut by Prudential Financial Inc.” was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2016/11/30/jazz-pharmaceuticals-plc-jazz-stake-cut-by-prudential-financial-inc.html.

Several analysts recently commented on the stock. Zacks Investment Research raised shares of Jazz Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Monday, November 14th. TheStreet lowered shares of Jazz Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research note on Tuesday, November 8th. Leerink Swann set a $182.00 target price on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Wednesday, November 9th. BMO Capital Markets cut their target price on shares of Jazz Pharmaceuticals PLC from $195.00 to $192.00 and set an “outperform” rating for the company in a research note on Wednesday, November 9th. Finally, Mizuho reduced their price target on shares of Jazz Pharmaceuticals PLC from $185.00 to $127.00 and set a “buy” rating for the company in a research report on Wednesday, November 9th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $179.91.

In other news, Director Kenneth W. O’keefe acquired 2,000 shares of the firm’s stock in a transaction that occurred on Monday, November 14th. The stock was purchased at an average price of $113.84 per share, for a total transaction of $227,680.00. Following the completion of the acquisition, the director now owns 12,107 shares in the company, valued at $1,378,260.88. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Michael Patrick Miller sold 200 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $126.17, for a total transaction of $25,234.00. Following the transaction, the senior vice president now owns 17,325 shares of the company’s stock, valued at approximately $2,185,895.25. The disclosure for this sale can be found here. Corporate insiders own 3.90% of the company’s stock.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.